IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: IMPT (Intensity Modulated Proton Therapy), IMRT (Intensity Modulated Radiation Therapy).
- Who it may be relevant to
- Registry conditions: Malignant Neoplasm of Anal Canal. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Phase III Randomised Control Trial of Intensity-Modulated Radiotherapy Using Photon Versus Proton With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer
Overview
The standard practice in management of carcinoma of anal canal is to treat patients with radiotherapy using the IMRT technique along with chemotherapy. It is known that while IMRT has reduced treatment related side effects as compared to the older radiation techniques, reducing these side effects further still remains a major challenge. These side-effects include gastrointestinal (diarrhea, altered bowel habits, weight loss, bleeding, obstruction), genitourinary (difficulties in passing urine, passing blood in urine, difficulty in holding urine) and hematologic toxicities (anemia, low platelet count and increased predisposition to infections). Proton therapy (IMPT) is a form of radiation treatment in which high doses can be delivered within the tumor while the surrounding normal tissues receive a lesser radiation dose. It is believed that these physical properties of proton therapy may help reduce the side effects of treatment. Patients will be randomly assigned to either receive IMRT or IMPT based treatment so as to see whether it is possible to reduce the acute treatment related toxicities. In this study, there is a 66.7% chance that the patient will get IMPT based treatment, which may be able to reduce the toxicities.
Interventions
- Radiation IMPT (Intensity Modulated Proton Therapy)
Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT. - Radiation IMRT (Intensity Modulated Radiation Therapy)
The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
Primary outcome measures
- Grade 3 or higher acute toxicity [Time frame: Upto 6 months post-last cytotoxic therapy.]
Secondary outcome measures (8)
- Local Failure [Time frame: 5 years since randomization]
- Regional Failure [Time frame: 5 years since randomization]
- Distant Relapse [Time frame: 5 years since randomization]
- Colostomy-free Survival [Time frame: 5 years since randomization]
- Disease-free Survival [Time frame: 5 years since randomization]
- Overall Survival [Time frame: 5 years since randomization]
- Treatment-related late toxicities [Time frame: 5 years since randomization]
- Patient-Reported Health-Related Quality of Life QLQ-C30 questionnaires [Time frame: 5 years since randomization]
Eligibility criteria
Inclusion criteria
- Age > 18 and < 80 years of age
- Histologically confirmed squamous cell carcinoma of the anal canal or distal rectum
- The patients may have TNM stage T1-2 N+M0 or T3-4 N0-1c M0 (UICC 8th edition)
- Involvement of lower para-aortic lymph nodes (till renal hilum) as the only site of disease extension on PET CECT may also be included as they receive radical chemoradiation as standard treatment.
- WHO or ECOG performance status 0-1
- HIV testing is known and HPV (P16) testing done on tissue sample.
- With suitable blood test values for standard concurrent chemotherapy (Hb > 10 mg/dL, ANC > 1.5 cells/mm3, Platelets > 100,000 cells/mm3, Creatinine < 1.5 x ULN, Bilirubin < 3 x ULN, ALT < 3 x ULN) as deemed by a medical oncologist in team.
- The patient must be expected to tolerate the treatment and be compliant for follow up.
- No contradiction for chemoradiation such as inflammatory bowel disease, pregnancy, etc.
- Willing to consent to participate in the study.
Exclusion criteria
- Two or more synchronous primary cancers.
- When prosthetic materials (e.g. hip prostheses) are present close to the target volume, it must be considered if this may introduce uncertainties in dose calculations, which may affect the treatment planning process.
- Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.
- Poor reliability for follow-up and treatment completion.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
India · 1 center
- Tata Memorial Centre — Mumbai
Identifiers
NCT: NCT06630793 · 4336